Adma Biologics (ADMA) Liabilities and Shareholders Equity (2011 - 2026)

Adma Biologics (ADMA) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $624.2 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 27.74% year-over-year to $624.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 billion (up 40.79% YoY) and the FY2025 annual result came in at $624.2 million, up 27.74% from the prior year.
• Liabilities and Shareholders Equity grew to $624.2 million in Q4 2025, from $568.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $624.2 million in Q4 2025 to a low of $232.8 million in Q2 2021.
• A 5-year average of $373.4 million and a median of $345.7 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 134.49% — and 2023, when it declined 5.53%.
• Tracing ADMA's Liabilities and Shareholders Equity over 5 years: stood at $276.3 million in 2021, then gained by 26.14% to $348.5 million in 2022, then decreased by 5.53% to $329.2 million in 2023, then jumped by 48.45% to $488.7 million in 2024, then climbed by 27.74% to $624.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $624.2 million (Q4 2025), $568.7 million (Q3 2025), and $558.4 million (Q2 2025), per Business Quant data.